若生智能
Drug Database
TA

tamsulosin

✓ Approved

Ethypharm Corp. · ADRA1A · 小分子

什么是 tamsulosin？

tamsulosin 是一种小分子，由Ethypharm Corp.研发。该药已获批，用于治疗相关适应症，给药途径：Oral (PO)。

药物档案

公司Ethypharm Corp.
药物类别小分子
分子靶点ADRA1A
给药途径Oral (PO)
状态Approved
来源： ClinicalTrials.gov, Ethypharm Corp.

作用机制

分子靶点

tamsulosin 作用于 1 个分子靶点：

ADRA1Aadrenoceptor alpha 1A (ALPHA1AAR, ADRA1C)
需要更深入的分析？Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

tamsulosin 针对 1 个适应症，涉及 1 个治疗领域。

治疗领域疾病/病症分期
Reproductive system and breast disordersBenign prostatic hyperplasia✓ Approved

相关研究文献

PubMedDiabetes, obesity & metabolism2026-08-04

Absence of Interaction Between 5α-Reductase Inhibitors and Glucocorticoids on Incidence of Myocardial Infarction in People With Type 2 Diabetes.

Tu Haolan H, Ju Chengsheng C, McGurnaghan Stuart J SJ, Blackbourn Luke A K LAK et al.

People with Type 2 diabetes experience higher cardiometabolic risk, and both synthetic glucocorticoids and use of 5α-reductase inhibitors have been individually linked to increased risk of myocardial infarction. We tested whether the increase in risk is exacerbated by co-prescription of both drugs. We performed a population-based cohort study in the Scottish Diabetes Research Network-National Diabetes Dataset (SDRN-NDS) and IQVIA Medical Research Data-UK (IMRD-UK). Patients with Type 2 diabetes aged ≥ 40 years receiving 5α-reductase inhibitors or tamsulosin, who were incident users of systemic glucocorticoids during 2006-2021 were included. We modelled the joint effect of 5α-reductase inhibitors and cumulative exposure to glucocorticoids on the risk of myocardial infarction using a time-varying Cox proportional hazards model. A total of 13 161 patients with Type 2 diabetes were included in SDRN-NDS and 15 084 in IMRD-UK. Mean age was 71.4 ± 9.6 and 72.3 ± 9.4 years, with mean follow-up of 4.7 (3.6) and 5.6 (4.0) years, respectively. Median (IQR) total glucocorticoids exposure was 210 (96-630) and 420 (200-1240) prednisolone-equivalent milligram. Risk for myocardial infarction was increased among users of 5α-reductase inhibitors (HR [95% CI]: SDRN-NDS, 1.21 [1.02-1.43]; IMRD-UK, 1.27 [1.02-1.59]) and per SD increase in cumulative glucocorticoid exposure (HR [95% CI]: SDRN-NDS, 1.09 [1.03-1.14]; IMRD-UK, 1.08 [1.01-1.15]). We did not observe a multiplicative interaction (SDRN-NDS, p = 0.44; IMRD-UK, p = 0.68) between the use of the two drugs. People with Type 2 diabetes exposed to 5α-reductase inhibitors or glucocorticoids are at an increased risk of myocardial infarction, although a multiplicative interaction between the use of the two drugs was not found.

PMID 42547757
阅读全文 →
PubMedCureus2026-08-02

Painless Ischemic Priapism Associated With Tamsulosin Use: A Case Report and Literature Review.

Rector Caitlin E CE, Lei Kevin K, Hubbard Lael L, Ovasapians Navasard N et al.

Tamsulosin, a selective α1-adrenergic antagonist prescribed for benign prostatic hyperplasia and expulsion of ureteral stones, carries a rare risk of priapism. We present a 59-year-old male with hypogonadism, hypertension, and hyperlipidemia who developed painless priapism 72 hours after initiating tamsulosin for ureterolithiasis. Despite the atypical absence of pain, penile blood gas analysis confirmed ischemic priapism. Initial treatment with intracavernosal phenylephrine (1000 mcg) failed, requiring bilateral corpus spongiosum shunts for resolution. A literature review revealed that many of the 14 existing cases identified occurred within 24 hours of drug initiation in middle-aged or older patients without additional risk factors. Approximately half responded to intracavernosal vasoconstrictors, while refractory cases required surgical intervention. To our knowledge, this is the first reported case of painless tamsulosin-induced ischemic priapism, emphasizing the importance of patient counseling and prompt evaluation of persistent erections regardless of pain intensity.

PMID 42540804
阅读全文 →
PubMedAmerican journal of men's health2026-07-30

Concurrent Jackstone Calculus and Prostate Cancer: Should They Be Treated Concurrently or Sequentially?

Tian Shuo S, Li Huijuan H, Jiang Yuliang Y, Wang Cheng C et al.

Jackstone calculus is a rare urinary stone morphology with a distinctive spiculated appearance, most often reported in the bladder and usually associated with urinary stasis or outlet obstruction. We report a 70-year-old man with 1 year of progressive dysuria and intermittent interruption of urinary stream despite tamsulosin and finasteride. Urinalysis showed pyuria, hematuria, and bacteriuria. Ultrasonography and pelvic computed tomography identified an irregular star-shaped bladder stone and marked prostatic enlargement, with an estimated prostate volume of approximately 125 mL on ultrasonography. Serum total prostate-specific antigen was 16.2 ng/mL, with a free-to-total ratio of 0.138. Systematic transrectal biopsy showed adenocarcinoma in 2 of 12 cores, Gleason score 3 + 3 = 6 (Grade Group 1). After multidisciplinary discussion, the patient underwent laparoscopic radical prostatectomy with concomitant intact stone removal. The 3.1-cm stone showed classic jackstone morphology. Final pathology showed Gleason 3 + 4 = 7 adenocarcinoma (Grade Group 2), upgraded from biopsy, with negative surgical margins. Telephone follow-up at 1, 3, and 12 months showed sustained improvement of lower urinary tract symptoms without recurrent urinary tract infection-related symptoms. Postoperative imaging and prostate-specific antigen data were unavailable. This case is relevant to men's health because a visually distinctive bladder stone may coexist with clinically relevant prostatic disease. In men with lower urinary tract symptoms and abnormal prostate-specific antigen values, bladder outlet obstruction, infection, or bladder stones should not preclude further oncologic evaluation. In selected patients in whom definitive prostate surgery is chosen, combined stone removal can be a practical single-stage approach.

PMID 42531155
阅读全文 →
PubMedGalen medical journal2026-07-25

Effect of Tamsulosin on Osteopontin Gene Expression in Preventing Ethylene Glycol-Induced Kidney Stone in Male Wistar Rats : Short title: Effect of Tamsulosin on Osteopontin Gene Expression.

Parvizrad Ramin R, Ghorbani Marghamlki Elahe E, Nikfar Somayeh S, Khalili Dermani Sara S

Tamsulosin, an α1-adrenergic receptor antagonist, has been proposed as a potential therapeutic agent against urolithiasis-induced renal damage. However, limited in vivo evidence exists regarding its renoprotective mechanisms. Forty male Wistar rats were randomly allocated into four groups (n=10/group): positive control, negative control (ethylene glycol-induced urolithiasis), prevention (tamsulosin administered simultaneously with ethylene glycol), and treatment (tamsulosin administered after model induction). Biochemical parameters including serum creatinine, urea, uric acid, calcium, and phosphorus were measured using rat-validated commercial kits (Pars Azmun, Iran). Normal ranges were defined based on published reference values. Gene expression was analyzed by qPCR using the 2^-ΔΔCt method. Study design and reporting followed the ARRIVE checklist. At day 30, the prevention group exhibited significantly lower serum creatinine (0.60 ± 0.08 mg/dL) compared to the negative control (0.98 ± 0.12 mg/dL, P0.01). Although urea levels were slightly higher in the prevention group (4.0 ± 0.7 mg/dL) versus the negative control (3.22 ± 0.6 mg/dL), the calculated BUN/creatinine ratio was significantly improved (46.7 vs. 33.0, P0.05). No significant changes were observed in serum calcium or phosphorus. Gene expression analysis showed upregulation of protective markers in the prevention group. In vivo findings on the beneficial effects of tamsulosin on the renal profile in ethylene glycol-induced urolithiasis illustrate its protective effects on the renal system through improvement of creatinine clearance and BUN/creatinine balance. This underscores its probable use as a protective therapeutic agent against renal injury of crystallization origin.

PMID 42499366
阅读全文 →
PubMedClinical pharmacology in drug development2026-07-20

Pharmacokinetics and Bioequivalence of Tamsulosin Hydrochloride Extended-Release Capsules in Healthy Chinese Volunteers: A Randomized, Open-Label, Crossover Study Under Fasting and Fed Conditions.

Du Lijie L, Wang Xiaolu X, Zhang Yi Y, Yang Jiamin J et al.

Tamsulosin hydrochloride is a long-acting, highly selective α1A receptor antagonist, primarily used to treat benign prostatic hyperplasia. It effectively alleviates lower urinary tract symptoms, including dysuria, nocturia, and urgency caused by prostate enlargement. This study aimed to evaluate the pharmacokinetics and bioequivalence of two tamsulosin extended-release capsules in Chinese volunteers under both fasting and fed conditions. A single-center, randomized, open-label, two-formulation, single-dose, two-period, two-way crossover design was used. A total of 64 healthy volunteers were enrolled, with 28 in the fasting group and 36 in the fed group. In the fasting group, each subject received a single dose of either the test or reference formulation in a randomized crossover design. In the fed group, volunteers consumed a high-fat meal 1 h before dosing. Blood samples were collected for up to 72 h post-dose, and plasma tamsulosin concentrations were measured using liquid chromatography-tandem mass spectrometry. The geometric mean ratios and 90% confidence intervals for key exposure metrics for both formulations under fasting and fed conditions were within the 0.8000-1.2500 bioequivalence range. Both formulations demonstrated bioequivalence under both conditions, and no severe adverse events were observed.

PMID 42474264
阅读全文 →
PubMedMedicine2026-07-18

A case report of primary prostate intravascular large B-cell lymphoma.

Yuan Fengju F, Liu Qian Q, Ding Wuwu W, Nie Jia J et al.

Primary intravascular large B-cell lymphoma (IVLBCL) is a rare and aggressive extranodal lymphoma that rarely affects the prostate. Its nonspecific clinical and laboratory features often lead to misdiagnosis as benign prostatic hyperplasia (BPH) or prostatitis, delaying appropriate treatment. We report a case of primary prostatic IVLBCL initially misdiagnosed as BPH, highlighting the diagnostic challenges and the importance of comprehensive pathological evaluation. A 75-year-old male presented with a 1-year history of a weakened urinary stream, dribbling, increased nocturia, and urinary urgency. Symptoms transiently improved with self-medication of the α1-blocker tamsulosin but later recurred. Histopathological examination revealed clusters of atypical tumor cells within the prostatic vasculature. Immunohistochemistry showed positivity for leukocyte common antigen, Vimentin, CD20, and CD79a, with a Ki-67 index > 90%. A final diagnosis of primary intravascular large B-cell lymphoma of the prostate was established. Following diagnosis, the patient and his family declined any antitumor therapy (including chemotherapy) and opted for best supportive care and were discharged against medical advice. The patient died 5 months after diagnosis without receiving any subsequent antitumor therapy. Prostatic IVLBCL is a diagnostic mimic of BPH and requires a high index of suspicion. Immunohistochemistry and molecular studies are essential for accurate diagnosis. Early recognition and appropriate chemotherapy can improve outcomes in this rare malignancy.

PMID 42470066
阅读全文 →

注册免费账户还可查看另外 2293 篇文献

免费注册查看全部文献 →

了解更多tamsulosin